技术指标
指标
数值
方向
MACD(12,26,9)
-0.072
卖出
RSI(14)
36.241
中性
STOCH(KDJ)(9,3,3)
21.648
中性
ATR(14)
0.100
高波动
CCI(14)
-97.322
中性
Williams %R
89.016
超卖
TRIX(12,20)
-1.306
卖出
StochRSI(14)
49.259
中性
搜索
ABVC Biopharma Inc
ABVC添加自选
1.010USD
-0.070-6.48%
收盘 07-31 16:00（美东）报价延迟15分钟
26.26M总市值
亏损市盈率 TTM
关键数据
1.080今开
1.080最高
25.44K成交量
亏损市盈率 TTM
--市盈率动
--股息TTM
0.10%换手率
1.080昨收
1.010最低
23.31K成交额
亏损市盈率静
2.42市净率
0.00%股息率 TTM
-52.72%ROA
5.48052周最高
0.30量比
-4.90M净利润
25.77M总股本
-0.3983每股收益TTM
0.54Beta
-106.65%ROE
0.88052周最低
6.48%振幅
100.00%毛利率
26.26M总市值
-7.45回报/风险
5.37%风险率
TradingKey ABVC Biopharma Inc股票评分
单位: USD 更新时间: 2026-07-31操作建议
ABVC Biopharma Inc当前公司基本面数据相对稳定，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名178/385位。机构持股占比非常高，中期看，股价处于平稳状态。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
ABVC Biopharma Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
ABVC Biopharma Inc亮点
亮点风险
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing products and technologies to combat various diseases. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. It also focuses on the development of new drugs and medical devices derived from plants.
分析师目标
根据
0
位分析师
--
评级
0.000
目标均价
0.00%
涨幅空间
ABVC Biopharma Inc新闻
即将为您带来更多新闻，敬请期待。。。
技术指标
移动平均线
指标
数值
方向
MA5
1.036
卖出
MA10
1.114
卖出
MA20
1.323
卖出
MA50
1.347
卖出
MA100
1.265
卖出
MA200
1.759
卖出
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
ABVC Biopharma Inc简介
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing products and technologies to combat various diseases. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. It also focuses on the development of new drugs and medical devices derived from plants.
公司代码ABVC
公司ABVC Biopharma Inc
CEOPatil (Uttam Yashwant)
网址https://abvcpharma.com/
公司股东
相关品种
热门品种
常见问题
ABVC Biopharma Inc(ABVC)的当前股价是多少？
ABVC Biopharma Inc(ABVC)的当前股价是 1.02。
ABVC Biopharma Inc的股票代码是什么？
ABVC Biopharma Inc的股票代码是ABVC。
ABVC Biopharma Inc股票的52周最高点是多少？
ABVC Biopharma Inc股票的52周最高点是5.48。
ABVC Biopharma Inc股票的52周最低点是多少？
ABVC Biopharma Inc股票的52周最低点是0.88。
ABVC Biopharma Inc的市值是多少？
ABVC Biopharma Inc的市值是26.26M。
ABVC Biopharma Inc(ABVC)股票的每股收益（EPS TTM）是多少
ABVC Biopharma Inc(ABVC)股票的每股收益（EPS TTM）是-0.39。